姜新,辛颖,罗景华,常鹏宇,冯奇,曲雅勤.参一胶囊联合放疗对晚期非小细胞肺癌疗效的临床观察[J].中华放射医学与防护杂志,2012,32(2):196-198
参一胶囊联合放疗对晚期非小细胞肺癌疗效的临床观察
Therapeutic effects of gensenoside-Rg3 combined with radiotherapy on advanced non-small cell lung cancer
投稿时间:2011-07-07  
DOI:10.3760/cma.j.issn.0254-5098.2012.02.022
中文关键词:  参一胶囊|放疗|非小细胞肺癌
英文关键词:Gensenoside-Rg3|Radiotherapy|Non-small cell lung cancer
基金项目:吉林省科技厅基金(200705221);吉林省发展与改革委员会基金(2010019-1)
作者单位E-mail
姜新 130021 长春,吉林大学第一医院肿瘤中心放疗科  
辛颖 吉林大学病理生物学教育部重点实验室  
罗景华 130021 长春,吉林大学第一医院肿瘤中心放疗科  
常鹏宇 130021 长春,吉林大学第一医院肿瘤中心放疗科  
冯奇 吉林大学第二医院放疗科  
曲雅勤 130021 长春,吉林大学第一医院肿瘤中心放疗科 quyaqin52@163.com 
摘要点击次数: 3408
全文下载次数: 2460
中文摘要:
      目的 应用参一胶囊联合放疗治疗Ⅲ、Ⅳ 期非小细胞肺癌(NSCLC),观察其临床疗效及不良反应。方法 63例Ⅲ、Ⅳ期NSCLC患者按简单随机化方法分为2组,治疗组,35例,给予放疗+参一胶囊处理;对照组,28例,放疗+安慰剂处理。比较2组患者的疗效及不良反应。结果 治疗组的近期疗效为57.14%, 显著高于对照组(32.14%,χ2=3.91,P<0.05),治疗组的中位生存期为14.2个月,显著长于对照组(11.2个月, χ2=2.07,P<0.05),治疗组的1年生存率为62.86%,显著高于对照组(39.29%, χ2=4.40,P<0.05);治疗组中各种常见的不良反应(除咳嗽、发热外)发生率,均低于对照组,但两组间差异无统计学意义。结论 参一胶囊联合放疗是治疗晚期NSCLC的有效方法,具有一定的减毒增效作用。
英文摘要:
      Objective To study the efficacy and toxicity of gensenoside-Rg3 (Rg3) combined with radiotherapy on non-small cell lung cancer (NSCLC) at advanced stages (Ⅲ and Ⅳ). Methods Sixty-three patients with stage Ⅲ or ⅣNSCLC were divided randomly into two groups: treatment group (n=35) treated with Rg3 combined with radiotherapy and control group (n=28) treated with radiotherapy alone.The efficacy and side effects were compared after the treatment. Results The response rate (CR+PR) of the treatment group was 57.14%, significantly higher than that of the control group (32.14%, χ2=3.91, P<0.05). The median survival time of the treatment group was 14.2 months, significantly longer than that of the control group (11.2 months, χ2=2.07,P<0.05). The one-year survival rate of the treatment group was 62.86%, significantly higher than that of the control group (39.29%, χ2=4.40,P<0.05). The incidence rates of side effects of the treatment group were all lower than those of the control group, but there were not significant difference. Conclusions Gensenoside-Rg3 combined with radiotherapy is effective for advanced stage NSCLC, with attenuation and synergistic effects.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭